ALIM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALIM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alimera Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.83 Mil. Alimera Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $64.49 Mil. Alimera Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $46.17 Mil. Alimera Sciences's debt to equity for the quarter that ended in Dec. 2023 was 1.41.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Alimera Sciences's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Alimera Sciences was 14.11. The lowest was -16.73. And the median was 0.96.
The historical data trend for Alimera Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | -8.88 | -5.58 | -16.73 | -2.17 | 1.42 |
Alimera Sciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-Equity | Get a 7-Day Free Trial | -2.17 | -2.35 | 1.39 | 1.32 | 1.42 |
For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Alimera Sciences's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Alimera Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.828 | + | 64.489) | / | 46.17 | |
= | 1.41 |
Alimera Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.828 | + | 64.489) | / | 46.17 | |
= | 1.41 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences (NAS:ALIM) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Alimera Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Margaret Pax | director | 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005 |
John Snisarenko | director | C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Pizzo Peter J. Iii | director | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Erin Parsons | director | 97 WILLISTON RD, BROOKLINE MA 02445 |
Caligan Partners Lp | 10 percent owner | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Ross D Demont | director | 51 PICKWICK ROAD, NEWTON MA 02465 |
C. Daniel Myers | other: Chairman Emeritus | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
David Edward Johnson | 10 percent owner | 590 MADISON AVENUE, NEW YORK NY 10022 |
Velan Capital Master Fund Lp | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Management Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Holdings Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Adam Morgan | director | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Investment Management Lp | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Spv I Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Balaji Venkataraman | 10 percent owner | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
From GuruFocus
By Marketwired • 10-11-2023
By sperokesalga sperokesalga • 03-24-2023
By GuruFocus Research • 08-03-2023
By sperokesalga sperokesalga • 05-17-2023
By sperokesalga sperokesalga • 02-27-2023
By Marketwired • 08-10-2023
By sperokesalga sperokesalga • 02-22-2023
By Ds*** Ds*** • 08-31-2022
By GuruFocus Research • 10-26-2023
By sperokesalga sperokesalga • 05-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.